Navigation Links
Doctors Report High Survival Rates for Hodgkin's Disease

Treatments are improving, and researchers even talk of a cure

WEDNESDAY, Nov. 7 (HealthDay News) -- Here's an example of progress in cancer treatment: a trial that produced long-term survival rates better than 90 percent and that is described as outmoded because it's been replaced by treatments that get even better results with fewer side effects.

The cancer is Hodgkin's disease, a type of lymphoma, or cancer of lymph tissue found in the lymph nodes, spleen, liver and bone marrow. And the new findings come from a European group led by French physicians. They are reporting five-year, disease-free survival as high as 98 percent for patients with the most favorable prognosis and in the mid-80s or better for those who showed up with a worse outlook.

The results are published in the Nov. 8 issue of the New England Journal of Medicine.

It's not an easy paper for a layman to read, because it is full of acronyms for the combination chemotherapy that was used (MOPP-ABV) and different cycles of radiation therapy. The study conclusion is that this "should be the standard treatment for Hodgkin's disease with favorable prognostic features."

But then there's the accompanying editorial by Dr. Volker Diehl of the University of Cologne, in Germany, which says that these results have been overtaken by time and better treatments.

MOPP-ABV now has been replaced by a different chemotherapy regimen, called ABVD, Diehl said, with even better survival rates. And research now is centered on such issues as possible reductions in radiation therapy, he said.

The standard procedure for people with early-stage Hodgkin's disease is to classify them as "higher" or "lower" risk on the basis of such things as age, symptoms and spread into lymph nodes, said Dr. Mitchell Smith, director of lymphoma service at the Fox Chase Cancer Center in Philadelphia.

About two-thirds of Hodgkin's cases are early stage. Those diagnosed in later stages get the same basic treatment, but more of it -- radiation plus cycles of ABVD chemotherapy. It has replaced MOPP-ABV because it causes fewer side effects, such as problems with sterility, Smith said.

"In a favorable group, you get close to 95 percent five-year survival with the right treatment," Smith said. "In the unfavorable group, it is close to 80 percent. Very few people relapse after five years."

The new approach is close monitoring of patients' condition during treatment to determine how much radiation therapy is needed -- not so much the amount but how large an area of the body should be irradiated. There is a hope that chemotherapy alone can cure some patients, Diehl's editorial said.

"Dr. Diehl and the German group are doing among the best Hodgkin work now," said Dr. Bart Kamen, chief medical officer of the Leukemia and Lymphoma Society. "It is an editorial right on the mark as far as I am concerned."

And Smith does not shy away from saying "cure," a word long shunned in cancer treatment. With a 95 percent disease-free rate after five years and few relapses after that, why not use the word when dealing with Hodgkin's disease, he asked.

"Most people will be comfortable with cure in five to 10 years," Smith said.

More information

You can learn more about Hodgkin's disease from the U.S. National Library of Medicine.

SOURCES: Mitchell Smith, M.D., director, lymphoma service, Fox Chase Cancer Center, Philadelphia; Bart Kamen, M.D., chief medical officer, Leukemia and Lymphoma Society, White Plains, N.Y.; Nov. 8, 2007, New England Journal of Medicine

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. Doctors Often Miss High Blood Pressure in Kids
3. One-fourth of HIV patients believe their doctors stigmatize them
4. Annual flu shot cuts need for doctors visits, hospitalization among children
5. Teens need to see their doctors more often
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
8. South Texas Doctors Report More Severe Cases of Community Staph Super Bug Hospitalizing Children
9. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
10. Doctors Debate Drugs vs. Surgery for Angina
11. UCI Medical Affiliates Inc. Opens a New Doctors Care Center in Anderson
Post Your Comments:
Related Image:
Doctors Report High Survival Rates for Hodgkin's Disease
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch ... solutions involving adult stem cell therapies to patients with chronic degenerative medical conditions. ... as a Registered Trademark (RTM). , Organizations are required to hold a registered ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA , ... now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. This ... cutting tools, such as the scalpel and high-speed drill, which can both cause patients ...
(Date:11/24/2015)... Angeles, CA (PRWEB) , ... November 24, 2015 , ... ... explored the different restrictions and variables that determine which patients are or are not ... those patients that have a BMI over 40, are more than 100 pounds overweight, ...
(Date:11/24/2015)... City, UT (PRWEB) , ... November 24, 2015 , ... ... Forbes Magazine. For a business, it is critical that the first impression be positive ... business, they are not likely to buy anything or want to return. They will ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... York , 24. November 2015 /PRNewswire/ ... Avery Breathing Pacemaker Systems, ist erfreut, die ... Clinical Consultant bekannt geben zu können. ...   --> Foto - ... (Schweden). Von 1984-1986 war er ...
Breaking Medicine Technology: